circRNA-LNP Platform for High-Yield CAR Delivery

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Although CAR-based immunotherapies hold substantial therapeutic potential, existing delivery vehicles both viral vectors and linear mRNA constructs are hampered by genotoxic hazards, short-lived transgene activity, and constrained manufacturability at scale. Our circRNA-LNP platform addresses these obstacles head-on through the synergy of covalently circularized RNA transcripts and an advanced ionizable lipid carrier, sustaining robust, genomically safe CAR expression over extended periods. We offer a complete suite of services encompassing custom circular RNA engineering, scalable LNP fabrication, and rigorous quality-control profiling, all optimized for translational development.

Introduction

Circular RNAs (circRNAs) function as stable, non-immunogenic transcripts that enable prolonged protein expression by resisting exonuclease-mediated degradation through their covalently closed loop structures. CircRNA-LNP platform harnesses these unique properties via proprietary lipid nanoparticle formulations that ensure efficient cellular delivery, robust cytosolic release, and minimized innate immune activation.

Fig.1 Functional roles of circRNAs. (OA Literature) Fig.1 Roles of circRNAs. ¹

Our Service

Our circRNA-LNP platform enables high-yield, durable CAR expression without genomic integration. Leveraging optimized circular RNA design and proprietary lipid nanoparticles, it ensures potent transfection, reduced immunogenicity, and scalable manufacturing. We deliver customized solutions for next-generation cell therapy, accelerating your pipeline from discovery to preclinical validation with unmatched efficiency and reproducibility.

What We Can Offer

Our comprehensive circRNA-LNP platform offers end-to-end solutions combining advanced RNA sequence optimization, tailored lipid nanoparticle formulation, and precise cell-specific targeting strategies to enable high-yield, robust CAR delivery for next-generation in vivo cellular immunotherapies.

Featured services of circRNA-LNP platform for high-yield CAR delivery at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

DNA plasmid template.
Peripheral blood mononuclear cells (PBMCs), primary T cells, or NK cells.

Key Steps:

Workflow of circRNA-LNP platform for high-yield CAR delivery at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

circRNA-LNP nanoformulation.
Engineered circRNA-CAR immune cells.

Key Advantages

Exceptional Structural Stability & Sustained Expression: The unique covalently closed circular structure of circRNA protects it from exonuclease-mediated degradation and significantly extends its intracellular half-life, thereby achieving a more prolonged and stable clinical expression of the CAR protein.
Efficient In vivo In Situ Reprogramming: Supporting targeted reprogramming of immune cells directly within the patient's body via intravenous injection, this platform completely bypasses the cumbersome and cost-prohibitive ex vivo cell engineering processes, enabling a truly off-the-shelf, ready-to-use therapy.
Optimized Safety Profile & Low Immunogenicity: The non-integrating, transient expression characteristic not only eliminates the risk of insertional mutagenesis and oncogenicity, but also imparts a manageable, self-attenuating clinical safety profile; furthermore, the purified and optimized sequence effectively evades host immune rejection.

FAQ

Q1: What drives the superior CAR protein yield of circRNA compared to its linear mRNA counterpart?

A1: Standard linear transcripts suffer from rapid degradation triggered by exposed terminal domains. By contrast, our platform utilizes a continuous, loop-shaped molecular architecture devoid of traditional terminal motifs, rendering the genetic payload impervious to enzymatic cleavage.

Q2: In what manner does this technology facilitate direct, systemic CAR gene transfer?

A2: We have engineered specialized lipid matrices optimized to package the distinct spatial configuration of circular transcripts, safeguarding them throughout systemic circulation. These vectors can be fine-tuned via surface modifications or distinct lipid compositions to selectively reprogram endogenous T lymphocytes or myeloid lineages following a standard intravenous administration.

Why Choose Us?

Leveraging our cutting-edge circRNA-LNP platform, we deliver unparalleled CAR expression through exceptional structural stability and optimized translation efficiency. By enabling direct, high-yield in vivo immune cell reprogramming, we eliminate complex ex vivo manufacturing, offering a safer, highly efficient, and truly off-the-shelf therapeutic solution for next-generation cellular immunotherapy.

Customer Reviews

"Our goal was to generate CAR-T cells directly in vivo to bypass the complex ex vivo manufacturing process. Traditional linear mRNA degraded too quickly to achieve therapeutic efficacy. Switching to this circRNA-LNP platform was a massive breakthrough. Because of the circular structure's resistance to exonucleases, we observed an incredibly high yield of CAR expression that persisted days longer than linear variants." Dr. Julian Mercer.

"In large-scale screening, maintaining a consistent high yield of CAR delivery is notoriously difficult. This service delivered uniform LNP encapsulation and reliable CAR expression dynamics across multiple donor samples." Prof. A* P*.

How to contact us?

Partner with us to revolutionize your cellular immunotherapy pipeline. Whether you are advancing an in vivo reprogramming project or seeking high-yield, stable delivery solutions, our experts are ready to tailor our circRNA-LNP platform to your needs. Contact our team today to discuss your project requirements and request a customized quote.

Reference

Bu, Tian et al. "Expanding the Potential of Circular RNA (CircRNA) Vaccines: A Promising Therapeutic Approach." International journal of molecular sciences vol. 26,1 379. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/ijms26010379.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.